Oxaliplatina Hikma (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in rapidly dividing cancer cells.

• Colorectal cancer: improves survival when used in combination regimens for metastatic or adjuvant therapy.
• Gastric cancer: contributes to tumor response as part of combination chemotherapy.
• Pancreatic cancer: used in selected protocols to enhance disease control.
• Ovarian cancer: may be incorporated into multi‑drug regimens for refractory disease.
• Esophageal cancer: added to standard regimens to increase response rates.
• Small‑cell lung cancer: occasionally used off‑label within clinical trials.

• Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑ and interstrand cross‑links, disrupting DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly proliferating tumor cells, while sparing most normal tissues at therapeutic doses.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during or after infusion.
• Peripheral neuropathy: tingling or numbness in hands and feet, often dose‑related.
• Diarrhea: watery stools that may require supportive care.
• Fatigue: generalized tiredness during treatment cycles.
• Myelosuppression: reduced blood cell counts, increasing infection risk.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm during infusion.
• Acute hemolytic anemia: rapid destruction of red blood cells.
• Severe neutropenia with fever: risk of life‑threatening infection.
• Cardiotoxicity: arrhythmias or myocardial ischemia in rare cases.
• Renal impairment: acute kidney injury requiring monitoring.
• Thrombotic microangiopathy: rare clotting disorder affecting small vessels.

Oxaliplatin requires careful monitoring and patient counseling before and during therapy.

• Renal function: assess baseline creatinine and adjust if impairment is present.
• Hepatic function: evaluate liver enzymes and bilirubin prior to dosing.
• Neuropathy risk: monitor for early signs of peripheral neuropathy and adjust dose as needed.
• Hematologic status: perform complete blood counts before each cycle to detect myelosuppression.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks.
• Storage: Store below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage.
• Highly protein‑bound drugs (e.g., warfarin): may displace oxaliplatin and alter plasma levels.

Moderate Interactions (Monitor Closely)

• Antiemetics (e.g., ondansetron): may be required to control infusion‑related nausea.
• Antioxidants (e.g., vitamin C, E): theoretical reduction of platinum‑induced cytotoxicity.
• CYP450 inducers/inhibitors: limited data, monitor for unexpected toxicity.
• Radiotherapy: concurrent use may enhance neurotoxicity.
• Blood transfusions: can affect laboratory monitoring of blood counts.